London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.

Clinical outcomes following implantation of a collagen copolymer epicrystallinian intraocular lens with a central hole for the correction of myopia

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Posterior chamber Phakic IOLS for correction of Myopia

Session Date/Time: Monday 15/09/2014 | 08:00-10:30

Paper Time: 08:06

Venue: Capital Hall B

First Author: : D.Almanzar SPAIN

Co Author(s): :    M. Naveiras   J. Alfonso   R. Montés-Micó        

Abstract Details


To assess the efficacy, predictability, safety and stability of a new model of epicrystallinian intraocular lens (IOL) made of Collamer (Implantable Collamer Lens: ICL, V4c Visian, Staar Surgical Co., Switzerland) for the correction of myopia.


Instituto Oftalmológico Fernández-Vega. Oviedo. Spain.


This study recruited patients who had undergone the implant of the new ICL V4C design whose main difference with previous models is the addition of a central hole that allows the flow of aqueous humor. This eliminates the need for Neodymium:YAG laser iridotomy or intraoperative iridectomy. The uncorrected visual acuity (UCVA) and corrected (BCVA), refractive error, intraocular pressure (IOP), endothelial cell count, central vault and adverse events were assessed at 24 months after implantation.


The study included a sample of 138 eyes of 70 patients. The mean spherical equivalent decreased from -8.73 ± 2.54 D to -0.03 ± 0.19 D at 6 months after implantation, 98.5% of eyes were in the range of ± 0.50 D and 100% for ± 1.00 D. The UCVA and DCVA averages were equal or superior to 1.0 at 92.1% and 95.0% of the cases respectively. Postoperatively IOP remained stable during follow-up. No significant increases in IOP or secondary cataracts were found. The average vault at 24 months was 482.7 ± 210.5 microns (Range of 90-970 microns) and the average endothelial cell loss was 8.5%


The V4c lens implant resulted effective, predictable, safe and stable for the correction of moderate to high myopia. This design, that avoids iridotomy or iridectomy, gave good results in terms of IOP.

Financial Interest:


Back to previous